End-of-day quote
Shenzhen S.E.
23:00:00 01/07/2024 BST
5-day change
1st Jan Change
27.4
CNY
-2.11%
+1.63%
+23.26%
Jafron Biomedical Co.,Ltd. Approves Profit Distribution
Jafron Biomedical Co.,Ltd. at the annual general meeting held on May 13, 2022 approved profit distribution with Cash dividend/10 shares (tax included): CNY 9.00000000.
Jafron Biomedical Co.,Ltd. Announces Final Dividend on A Shares for 2023, Payable on 31 May 2024
05-24
CI
Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023
04-26
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-25
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
04-03
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
04-03
CI
Jafron Biomedical Co.,Ltd.'s Equity Buyback announced on July 17, 2023, has closed with 24,242,904 shares, representing 3% for CNY 500 million.
04-02
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
01-02
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
27/10/23
CI
Zhuhai Jianfu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 15 million in funding from Jafron Biomedical Co.,Ltd.
22/10/23
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
12/10/23
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
18/08/23
CI
Jafron Biomedical Co.,Ltd. announces an Equity Buyback for CNY 500 million worth of its shares.
17/07/23
CI
Jafron Biomedical Co.,Ltd. authorizes a Buyback Plan.
16/07/23
CI
Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023
24/05/23
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
27/04/23
CI
Jafron Biomedical Co.,Ltd. Approves the Cash Dividend for 2022
24/04/23
CI
Jafron Biomedical Co.,Ltd. Approves Director Elections
24/04/23
CI
Jafron Biomedical Co.,Ltd. Announces Profit Distribution Proposal for 2022
31/03/23
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
30/03/23
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
27/10/22
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
25/08/22
CI
Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022
05/06/22
CI
Jafron Biomedical Co.,Ltd. Approves Profit Distribution
16/05/22
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
13/04/22
CI
Jafron Biomedical Boosts Final Dividend as 2021 Profit Surges 37%
13/04/22
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Jafron Biomedical Co Ltd is a China-based company principally engaged in the research, development, production and sales of biomaterials and high-tech medical devices. The Company is mainly engaged in the provision of blood purification products, disposable blood perfusion device, disposable plasma bilirubin adsorber, deoxyribonucleic acid (DNA) immunosorbent columns, cytokine adsorption column, haemodialysis powder, blood purification equipment and other products. The Company's products are widely used in the treatment of uremia, poisoning, severe liver disease, autoimmune diseases and multi-organ failure. The Company mainly conducts its businesses in the domestic market and overseas markets.
More about the company
Last Close Price
27.4
CNY
Average target price
33.94
CNY
Spread / Average Target
+23.89%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1